UCB SA research snapshot
UCB AI stock analysis reads UCB SA as a Brussels-based specialty biopharmaceutical company whose growth is increasingly concentrated in Bimzelx, supported by Rystiggo, Zilbrysq, Fintepla and Evenity. At the August 3, 2026 data cutoff, UCB traded near EUR 221.60 on Euronext Brussels, with a market capitalization near EUR 43.10 billion and an AI research score of 68 out of 100. The company reported strong H1 2026 results on July 30 and raised its 2026 guidance, yet the shares fell about 13.5% that day because Bimzelx sales slightly missed expectations, investors questioned the quality of the earnings beat, and management flagged higher second-half costs. This page uses scenarios, technical levels, and source-backed data for informational research, not investment advice.
Current price
EUR 221.60
Market cap
EUR 43.10 billion
AI score
68 / 100
Rating
High-quality specialty biopharma, but the July 30 earnings-quality selloff needs scrutiny
Trend status
Downtrend after a 13.5% post-results drop on July 30, now consolidating well below the 52-week high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | UCB develops and commercializes specialty medicines in immunology and neurology, with five growth drivers (Bimzelx, Rystiggo, Zilbrysq, Fintepla, Evenity) that drove H1 2026 adjusted gross margin to 82% and adjusted EBITDA margin to 40.7%. | High |
| Moat | Patents, clinical evidence, specialist physician relationships, and manufacturing capability support the moat. Bimzelx has four head-to-head superiority wins, but mature products face loss of exclusivity and long-term pricing pressure. | Medium-high |
| Management | CEO Jean-Christophe Tellier and CFO Sandrine Dufour have delivered a decade of growth, raised 2026 guidance twice, lifted Bimzelx peak-sales ambition to at least EUR 7 billion, and added Candid and Neurona to the pipeline. The July 30 earnings-quality questions put execution under scrutiny. | Medium-high |
| Financial trend | FY2025 revenue rose 26% to EUR 7.74 billion with core EPS of EUR 9.99. H1 2026 revenue rose 22% to EUR 4.27 billion with core EPS of EUR 6.84 and adjusted EBITDA margin up to 40.7%. | High |
| Valuation | At EUR 221.60, UCB trades near 19x consensus 2026 core EPS of EUR 11.87 and about 28x trailing IFRS EPS, with a 0.65% dividend yield. The multiple assumes Bimzelx keeps compounding and pricing holds. | Medium |
| Technical trend | The stock fell 13.5% on July 30 to EUR 217.00, bounced to EUR 222.90 on July 31, and is consolidating near EUR 221, about 23% below the EUR 289.50 52-week high. | Medium |
| Risk level | Risks include Bimzelx competition and net pricing erosion, Briviact and Vimpat loss of exclusivity, binary pipeline readouts, European healthcare pricing, EUR/USD translation, and integration of the Candid and Neurona acquisitions. | High |
| AI confidence | Financial data is verifiable, but AI cannot convert pipeline uncertainty or the post-results earnings-quality debate into dependable price predictions. | High data confidence |
| Investment certainty | Medium. The business is compounding and margins are expanding, but the current price already discounts strong execution, so the margin of safety depends on Bimzelx momentum, pricing discipline, and pipeline delivery. | Medium |
UCB AI stock forecast
The UCB AI stock forecast uses scenario ranges around the EUR 221.60 cutoff price and the Visible Alpha consensus of EUR 11.87 core EPS for 2026 and EUR 16.38 for 2028. It does not claim a precise prediction. The three-year framework points to a bearish area near EUR 170 to 210, a base area near EUR 280 to 330, and a bullish area near EUR 360 to 450, before dividends.
EUR 360 to EUR 450
More likely if Bimzelx sustains high-teens to 20% plus growth and moves toward the EUR 7 billion peak-sales ambition, head-to-head wins convert into market share, pipeline assets such as dapirolizumab pegol and bepranemab deliver, and European and US pricing holds. This roughly matches 22x on a 20% EPS growth path.
EUR 280 to EUR 330
More likely if core EPS compounds near the Visible Alpha consensus path of about EUR 16.38 by 2028, Bimzelx grows as modeled, legacy products decline gradually, and the market keeps a roughly 18x forward core multiple.
EUR 170 to EUR 210
More likely if Bimzelx faces faster pricing erosion or competition, the earnings-quality concerns from July 30 prove to be a trend, Briviact and Vimpat losses of exclusivity hit harder, or the EUR weakens further against the USD, reducing reported results.
UCB AI technical analysis
UCB AI technical analysis is cautious as of the August 3, 2026 cutoff. The stock is consolidating near EUR 221 after a 13.5% crash on July 30 that pushed the close to EUR 217.00 on the heaviest volume of the recent period. The short-term trend is down from the EUR 289.50 52-week high, and the July 30 to August 3 price action defines a EUR 214 to 228 range. These levels are snapshots from daily Euronext data, not forecasts.
| Level | Value | Why it matters |
|---|---|---|
| Current price | EUR 221.60 | Intraday price on August 3, 2026, against a July 31 close of EUR 222.90. |
| Near support | EUR 214 to EUR 217 | The July 30 crash low (EUR 214.00 intraday) and close (EUR 217.00). A daily close below this zone would signal another leg down. |
| Secondary support | EUR 195 to EUR 200 | A round-number zone between the current level and the 52-week low of EUR 181.15. It has not been tested recently. |
| Near resistance | EUR 228 to EUR 230 | The July 31 high (EUR 228.40) and the August 3 high (EUR 228.50). A sustained close above this area would improve the short-term setup. |
| 52-week high | EUR 289.50 | Major overhead resistance. A move back above this level would resume the long-term uptrend. |
| 52-week low | EUR 181.15 | The lowest print of the past 52 weeks. A decisive break below it would signal a major trend breakdown. |
| Momentum | Short-term bearish | The July 30 selloff broke the early-July consolidation and the stock has traded below EUR 230 since. July 30 volume near 857,000 shares was roughly four times the recent average, confirming institutional selling. |
| Volume | July 30 volume near 857,000 shares | Against an average near 210,000 to 224,000 shares. Lower volume since then means trend signals are less reliable. |
| Volatility | EUR 181.15 to EUR 289.50 52-week range | The roughly EUR 108 range equals about 49% of the current price, a wide band consistent with a single-stock biopharma exposed to trial data and results. |
| Invalidation | Daily close below EUR 214 | A close below the July 30 crash low would invalidate a stabilization framework and require a fresh chart review. |
UCB AI trading strategy
The UCB AI trading strategy is a rules-based research framework for a European biopharma stock in a corrective phase after a sharp earnings reaction. It is not personal advice. Refresh it with live Euronext prices, Bimzelx sales data, trial readouts, and your own position-sizing rules before any trade.
Wait for UCB to reclaim and hold above the EUR 228 to 230 zone on above-average volume, and for Bimzelx quarterly net sales to keep accelerating while management confirms the raised guidance. A move back toward EUR 240 to 250 would strengthen the setup.
A daily close below EUR 214 or a negative Bimzelx or pipeline readout should invalidate the trend setup. Lower liquidity means stops should allow for wider spreads.
If UCB holds above EUR 214 and forms a reversal pattern with declining selling volume, a measured reversion toward EUR 228 to 240 is feasible. Compare the price reaction with Bimzelx sales momentum, second-half cost commentary, and EUR/USD trends.
Do not average down below EUR 214 without a predefined loss limit and a catalyst thesis. European biopharma can gap on trial or pricing news that bypasses typical stop assumptions.
Track Bimzelx quarterly net sales and net pricing, HS and psoriatic arthritis share, Briviact and Vimpat erosion, pipeline phase transitions (pediatric Bimzelx, galvokimig, bepranemab, dapirolizumab pegol, rezanecel), adjusted EBITDA margin, net financial debt, free cash flow, and EUR/USD.
Reduce confidence if Bimzelx growth decelerates, earnings-quality questions persist, second-half margins disappoint, or net debt from the Candid and Neurona acquisitions weighs on the balance sheet.
Investment research summary
UCB turns research in immunology and neurology into patented specialty medicines prescribed by specialists for severe chronic conditions such as plaque psoriasis, hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, generalized myasthenia gravis, epilepsy, and osteoporosis.
The moat rests on intellectual property, clinical evidence (Bimzelx holds four head-to-head superiority wins), specialist physician relationships, manufacturing capability, and a focused commercial organization. It is strongest in differentiated new biologics and weakest for mature products approaching loss of exclusivity such as Briviact and Vimpat.
The thesis can fail if Bimzelx growth slows or faces net pricing erosion, pipeline readouts miss, legacy neurology products lose share faster than modeled, European healthcare pricing reforms compress margins, or the Candid and Neurona acquisitions fail to create value. The July 30 selloff shows the market is already discounting some of these outcomes.
Tellier and Dufour have compounded a decade of growth, raised 2026 guidance twice, lifted Bimzelx peak-sales ambition to at least EUR 7 billion, and expanded the pipeline through the Candid and Neurona deals. The open questions are capital allocation discipline and whether second-half earnings hold up.
Aging populations, chronic disease prevalence, and biologic innovation support long-term demand for specialty medicines, and UCB is well placed in immunology and neurology. The same industry carries binary clinical, regulatory, pricing, and patent-cycle risks that affect individual company outcomes.
At EUR 221.60, UCB trades near 19x consensus 2026 core EPS and about 28x trailing IFRS EPS with a 0.65% dividend yield. Margin of safety depends on whether Bimzelx and the pipeline can sustain the embedded growth expectations after the post-results de-rating.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| UCB price and market capitalization | EUR 221.60 intraday on August 3, 2026; market cap EUR 43.10 billion | Google Finance UCB:EBR quote | August 3, 2026 |
| Market capitalization verification | EUR 43.10 billion = EUR 221.60 x 194.51 million shares, a 0.01% deviation from the reported value | financial_rigor.py market cap verification and Google Finance share data | August 3, 2026 |
| Recent daily closes | July 30 close EUR 217.00 (-13.51%), July 31 close EUR 222.90 (+2.72%), August 3 trading near EUR 221.60 to EUR 224.40 | StockAnalysis EBR:UCB history (S&P Global Market Intelligence) | August 3, 2026 |
| FY2025 revenue and earnings | Revenue EUR 7.74 billion (+26%, +29% CER); net sales EUR 7.39 billion (+32%, +35% CER); group profit EUR 1.56 billion; core EPS EUR 9.99 | UCB full-year 2025 results press release, February 26, 2026 | August 3, 2026 |
| H1 2026 results | Revenue EUR 4.27 billion (+22%, +27% CER); core EPS EUR 6.84; adjusted EBITDA EUR 1.74 billion at 40.7% of revenue; group profit EUR 1.11 billion | UCB half-year 2026 results press release, July 30, 2026 | August 3, 2026 |
| Bimzelx H1 2026 net sales | EUR 1.53 billion, up 91% year over year (>100% CER); peak sales guidance raised to at least EUR 7 billion; over 135,000 patients treated | UCB half-year 2026 results press release, July 30, 2026 | August 3, 2026 |
| 2026 financial guidance | Revenue growth raised to low-teens to mid-teens at CER; adjusted EBITDA growth raised to mid-teens to low-twenties at CER (mid-twenties to low-thirties excluding 2025 one-offs) | UCB half-year 2026 results press release, July 30, 2026 | August 3, 2026 |
| Consensus core EPS | Visible Alpha consensus dated August 3, 2026: 2026 core EPS EUR 11.87, 2027 EUR 13.70, 2028 EUR 16.38, 2029 EUR 19.39 | UCB shareholders page, Visible Alpha consensus | August 3, 2026 |
| Analyst price targets | 20 analysts, consensus Buy, average target EUR 286.21, low EUR 208, high EUR 340 | StockAnalysis EBR:UCB forecast (S&P Global Market Intelligence) | August 3, 2026 |
| TTM EPS and valuation ratios | TTM IFRS EPS about EUR 8.02 to 8.03; trailing P/E about 27.6x; forward core P/E about 18.7x; price-to-book about 4.4x | Google Finance and Yahoo Finance UCB.BR statistics | August 3, 2026 |
| Dividend | EUR 1.45 gross for FY2025 (ex-date May 4, 2026, paid May 6, 2026), about 0.65% yield at EUR 221.60 | UCB shareholders page | August 3, 2026 |
| 52-week range | EUR 181.15 low to EUR 289.50 high | StockAnalysis EBR:UCB and Google Finance | August 3, 2026 |
| Net financial debt | EUR 2.82 billion at June 30, 2026 (0.8x adjusted EBITDA), versus net cash of EUR 7 million at December 31, 2025, driven by the Candid and Neurona acquisitions | UCB investor performance page | August 3, 2026 |
| Ownership structure | Financiere de Tubize about 36% (36.29% at June 30, 2026); treasury shares about 2%; free float about 62% | UCB shareholders page and Financiere de Tubize half-year 2026 report | August 3, 2026 |
This UCB AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, Euronext quote snapshots, broker consensus, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, trial results, regulatory decisions, pricing changes, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
